Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11769MR)

This product GTTS-WQ11769MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11769MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4445MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ15765MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ8675MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ868MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ1757MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ9600MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ6810MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ14347MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW